Evidence map›Paper›PMID 33530801›Full record

ArticleThe Journal of international medical research2021

1,25-(OH)

Shasha Tian, Xiaopeng Yang, Jianwu Wang, Jing Luo, Hui Guo

Open access · goldAbstract read
In one paragraph

Article in The Journal of international medical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Metabolic Reprogramming and Renal Fibrosis.Frontiers in medicine · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Shasha TianDepartment of Nephrology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.ORCID https://orcid.org/0000-0002-5306-410X
Xiaopeng YangDepartment of Nephrology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Jianwu WangDepartment of Nephrology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Jing LuoDepartment of Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Hui GuoDepartment of Nephrology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Shanxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the effects of 1,25(OH)

methodsA total of 54 male Sprague Dawley rats were randomly divided into three groups: sham-operation group, UUO group, and UUO plus calcitriol (3 ng/100 g) group. Renal tissue was excised for histological examination by immunohistochemistry and Western blot, and for gene expression analysis using real-time polymerase chain reaction.

results1,25(OH)

conclusionTreatment with 1,25(OH)

Indexed as

Kidney DiseasesUreteral ObstructionAMP-Activated Protein KinasesAnimalsFibrosisKidneyMaleRatsRats, Sprague-DawleyTOR Serine-Threonine KinasesTransforming Growth Factor beta1AMP-Activated Protein KinasesmTOR protein, ratTOR Serine-Threonine KinasesTransforming Growth Factor beta11,25-(OH)2D3AMPKα/mTORrenal interstitial fibrosisTGF-β1UUO

Identifiers

PMID33530801
PMCPMC7871069
OpenAlexW3128772743

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.